Drug Approval | February 24, 2026
FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
In 2025, over 1 million patients accessed Lilly treatments through LillyDirect
The drug’s safety profile in LIBRETTO-432 aligned with previous selpercatinib studies, showing no unexpected concerns
The trial targeted a patient population with high BMI and extensive skin involvement, averaging over 39 kg/m²
The trial, which compared Retevmo to placebo, met its primary endpoint with a “highly statistically significant and clinically meaningful improvement” in investigator-assessed EFS for patients with stage II–IIIA disease
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
Collaboration funds participating biotechs to access Lilly predictive models through the Revvity Signals Xynthetica offering
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
